• Hims & Hers launched a USD 300 million private offering of convertible senior notes due 2032, with an option for initial purchasers to buy up to an additional USD 45 million.
• Proceeds earmarked to support international expansion, including the proposed acquisition of Eucalyptus expected to close in mid-2026, alongside investment in technology, fulfillment infrastructure, and AI capabilities.
• Notes mature on June 1, 2032, with semi-annual interest; conversions may be settled in cash, shares, or a mix at the issuer’s option.
• Redemption permitted from June 6, 2029 if the stock trades above 130% of the conversion price for a specified period, with repurchase rights triggered by certain fundamental change events.
• Capped call transactions expected to reduce dilution tied to conversions, with additional hedging activity potentially affecting the stock price around pricing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hims & Hers Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260517417885) on May 18, 2026, and is solely responsible for the information contained therein.